Disease · MONDO_0100313
Targets90
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 90
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 3 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| AGTR1 | Type-1 angiotensin II receptor | 2 | Type-1 angiotensin II receptor antagonist | Phase 3 | https://conductscience.org/library/genes/185 | Drugs and targets |
| EDNRA | Endothelin-1 receptor | 2 | Endothelin receptor ET-A antagonist | Phase 3 | https://conductscience.org/library/genes/1909 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 2 | FK506-binding protein 1A inhibitor | Phase 2 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| PPARG | Peroxisome proliferator-activated receptor gamma | 2 | Peroxisome proliferator-activated receptor gamma agonist; Peroxisome proliferator-activated receptor gamma antagonist | Phase 2 | https://conductscience.org/library/genes/5468 | Drugs and targets |
| ALDH5A1 | Succinate-semialdehyde dehydrogenase, mitochondrial | 1 | Succinate semialdehyde dehydrogenase inhibitor | Phase 2/3 | https://conductscience.org/library/genes/7915 | Drugs and targets |
| ATP4A | Potassium-transporting ATPase | 1 | Potassium-transporting ATPase inhibitor | Unknown | https://conductscience.org/library/genes/495 | Drugs and targets |
| ATP4B | Potassium-transporting ATPase | 1 | Potassium-transporting ATPase inhibitor | Unknown | https://conductscience.org/library/genes/496 | Drugs and targets |
| BTK | Tyrosine-protein kinase BTK | 1 | Tyrosine-protein kinase BTK inhibitor | Phase 2 | https://conductscience.org/library/genes/695 | Drugs and targets |
| C3 | Complement C3 | 1 | Complement C3 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/718 | Drugs and targets |
| CCN2 | CCN family member 2 | 1 | Connective tissue growth factor inhibitor | Phase 1 | https://conductscience.org/library/genes/1490 | Drugs and targets |
| CCR2 | C-C chemokine receptor type 2 | 1 | C-C chemokine receptor type 2 antagonist | Phase 2 | https://conductscience.org/library/genes/729230 | Drugs and targets |
| CD80 | T-lymphocyte activation antigen CD80 | 1 | T-lymphocyte activation antigen CD80 inhibitor | Phase 2 | https://conductscience.org/library/genes/941 | Drugs and targets |
| CD86 | T-lymphocyte activation antigen CD86 | 1 | T-lymphocyte activation antigen CD86 inhibitor | Phase 2 | https://conductscience.org/library/genes/942 | Drugs and targets |
| COXFA4 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 1/2 | https://conductscience.org/library/genes/4697 | Drugs and targets |
| COXFA4L2 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 1/2 | https://conductscience.org/library/genes/56901 | Drugs and targets |
| GPD2 | Glycerol-3-phosphate dehydrogenase, mitochondrial | 1 | Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor | Phase 1/2 | https://conductscience.org/library/genes/2820 | Drugs and targets |
| GUCY1A1 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 2 | https://conductscience.org/library/genes/2982 | Drugs and targets |
| GUCY1A2 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 2 | https://conductscience.org/library/genes/2977 | Drugs and targets |
| GUCY1B1 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 2 | https://conductscience.org/library/genes/2983 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100313/targets